GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B5512 JNJ 5207787Summary: NPY Y2 antagonist
-
B5654 CYM 9484Summary: neuropeptide Y (NPY) Y2 receptor antagonist
-
B6760 GR 231118Summary: neuropeptide Y (NPY) Y1 receptor antagonist
-
B7047 BIBO 3304 trifluoroacetateSummary: NPY Y1 receptor antagonist,highly selective
-
B7155 BIBP 3226 trifluoroacetateTarget: NPY Receptors|NPFF receptorSummary: Mixed NPY Y1 and NPFF receptor antagonist
-
B7327 BMS 193885Summary: Competitive NPY Y1 receptor antagonist
-
B7405 S 25585Summary: neuropeptide Y (NPY) Y5 receptor antagonist
-
B7427 LU AA33810Summary: neuropeptide Y (NPY) Y5 receptor antagonist
-
B7466 NPY 5RA972Summary: neuropeptide Y Y5 receptor antagonist
-
B7528 SF 11Summary: NPY Y2 antagonist